Article info
Current controversy
Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy
- Correspondence to Dr Marielle S Gross, Johns Hopkins University Berman Institute of Bioethics, Baltimore, MD 21205, USA; mariellesophiagross{at}gmail.com
Citation
Respect women, promote health and reduce stigma: ethical arguments for universal hepatitis C screening in pregnancy
Publication history
- Received July 8, 2019
- Revised January 3, 2020
- Accepted January 13, 2020
- First published February 13, 2020.
Online issue publication
September 23, 2020
Article Versions
- Previous version (23 September 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Modelling the potential clinical and economic impact of universal antenatal hepatitis C (HCV) screening and providing treatment for pregnant women with HCV and their infants in Egypt: a cost-effectiveness study
- Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy
- Prevalence of hepatitis C among pregnant women attending an inner London obstetric department: uptake and acceptability of named antenatal testing
- Improving hepatitis C screening and diagnosis in patients born between 1945 and 1965 in a safety-net primary care clinic
- Changes in hepatitis C burden and treatment trends in Europe during the era of direct-acting antivirals: a modelling study
- Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar
- Hepatitis C in pregnancy
- Towards HCV elimination among people who inject drugs in Hai Phong, Vietnam: study protocol for an effectiveness-implementation trial evaluating an integrated model of HCV care (DRIVE-C: DRug use & Infections in ViEtnam–hepatitis C)
- Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial
- On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: a prospective cohort study from 2013 to 2017